Thermo Fisher Scientific EPS (Diluted) decreased by 15.0% to $4.43 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.3%, from $3.98 to $4.43. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows relatively stable performance with a -2.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.61 | $4.79 | $4.18 | $5.61 | $4.22 | $3.79 | $4.01 | $3.32 | $3.51 | $4.42 | $4.20 | $3.46 | $4.04 | $4.25 | $4.78 | $3.98 | $4.28 | $4.27 | $5.21 | $4.43 |
| QoQ Change | — | +3.9% | -12.7% | +34.2% | -24.8% | -10.2% | +5.8% | -17.2% | +5.7% | +25.9% | -5.0% | -17.6% | +16.8% | +5.2% | +12.5% | -16.7% | +7.5% | -0.2% | +22.0% | -15.0% |
| YoY Change | — | — | — | — | -8.5% | -20.9% | -4.1% | -40.8% | -16.8% | +16.6% | +4.7% | +4.2% | +15.1% | -3.8% | +13.8% | +15.0% | +5.9% | +0.5% | +9.0% | +11.3% |